2
Since 1999, significant decreases in opiate-related deaths in NSW have been reported.
2 A significant reduction in the availability of heroin, which started in December 2000, has also been reported. 3 This reduction can be partially attributed to increased drug law enforcement activities that have reduced the supply of heroin into Australia. 4 In May 1999, just before the reduction in the availability of heroin occurred, the NSW Government called for a Drug Summit, which took a 'whole of government' approach to illicit drug problems. The NSW Drug Summit provided over $176 million in additional funds to implement a four-year strategy of harm minimisation. 5 A significant amount of these funds were provided to the NSW Department of Health, to expand the treatment options available and their accessibility for opiatedependent people.
OPIATE OVERDOSE AND HEALTH TREATMENT OPTIONS FOR OPIATE USERS IN NEW SOUTH WALES, 1999-2002
continued on page 126 Data on methadone and buprenorphine treatment is available from an administrative database, maintained by the Pharmaceutical Services Branch, NSW Department of Health, which monitors the extent of prescribing and dosing of both drugs across New South Wales. Due to the ongoing nature of methadone and buprenorphine treatment, numbers are extracted for the last day of each month to determine the population receiving treatment at a point in time.
Data on clients of other drug treatment services are collected by the NSW Minimum Data Set on Drug and Alcohol Treatment Services, which commenced in July 2000. This dataset is maintained by the Centre for Drug and Alcohol, NSW Department of Health. The unit of measurement is based on an episode of treatment, where a client is provided with treatment in one setting with no change to the main treatment type or drug of principal concern. Based on this definition, clients may be admitted to more than one treatment in a month. This data collection does not include methadone and buprenorphine treatment.
Statistical analysis
In the comparative analyses between years, chi-square statistics were used to examine significant differences between proportions for males and females. T-tests were employed to compare mean age between years and for different treatment types. Significance is based on p<0.05. To measure the relationship between number of opiaterelated fatalities and number of clients on methadone and buprenorphine treatment, the Pearson product moment correlation coefficient is used. The Pearson product moment correlation coefficient is an index that ranges between -1 and 1 and reflects the extent of a linear relationship between two sets of data. Figure 1 shows the number of deaths where an opiate was detected by DAL. To gauge the impact of treatment on the opiate dependent population, the trend in deaths where an opiate is detected is mapped with the trend in the number of people on methadone and buprenorphine treatment ( Figure 6 ). A decrease in opiate-related fatalities is linked to an increase in methadone and buprenorphine treatment. A value of r=-0.79 would suggest that there was a strong negative relationship between the two trends.
RESULTS

Overdose
DISCUSSION
According to the three different sources used to measure fatal and non-fatal opiate overdose, the number of overdoses steadily decreased between the beginning of 1999 through It is commonly believed that many overdose deaths occur among young, relatively inexperienced opiate users. However, studies have shown that the average age of overdose deaths ranges from 29.4 years to 31 years, having increased from 24.2 years in 1979. 6 This study found the average age of death was older again at 33 years, the average age of presentation to an emergency department was 34.5 years, and the average age of methadone and buprenorphine treatment clients was 35.5 years. This may reflect an ageing of the opiate dependent population.
NUMBER OF CLOSED EPISODES OF TREATMENT (EXCLUDING METHADONE AND BUPRENORPHINE) FOR OPIATE USERS EACH MONTH IN NSW FOR THREE TYPES OF TREATMENT, JULY 2000-MARCH
The literature suggests that males and females are equally likely to experience a non-fatal overdose; however, males are more likely to die from an opiate overdose. 6 In this study, males represented over 85 per cent of overdose deaths in 2001-2002, while males represented 61 per cent of overdose presentations to emergency departments and 64 per cent of the population receiving treatment with methadone and buprenorphine.
The NSW Drug Summit resulted in increased availability and access to drug treatment, particularly to the NSW methadone and buprenorphine treatment program. 5 Entry into the methadone and buprenorphinetreatment program is a common, if not primary, means by which heroin users seek to leave the heroin market or limit their use of heroin. Entry into treatment usually results in improvement in health and social functioning. 7 This article has documented trends in fatal and non-fatal opiate overdose and treatment for opiate users in NSW and explored the implications of these trends in the context of the NSW Drug Summit enhancements and the heroin drought. This discussion has not attempted to attach causality to why certain trends in heroin overdose have decreased, as a myriad of factors may be responsible. Examples of some of these factors include the expansion of the treatment and law enforcement programs, enhanced state investment in drug programs, and the heroin shortage.
Regardless of the reason, it is essential that the achievements of fewer fatal and non-fatal overdoses, and increased treatment for opiate users, be maintained if heroin availability increases. It is important to continue monitoring these trends to enable a swift policy response to future emerging issues. Deaths where an opiate is detected
MBT clients Opiate deaths
The Centre for Drug and Alcohol and the Centre for Epidemiology and Research at the NSW Department of Health have developed a web-based interface that allows access to reports on drug related morbidity and mortality in NSW. This article introduces this system, the Drugs Related Outcomes: Population Surveillance (DROPS), describing its development and how it can be used to access drug-related health statistics for the NSW population.
BACKGROUND
A range of health data related to the use of illicit and injecting drugs is routinely collected for the NSW population; however, until recently there was no system to analyse and regularly report on these data. Also, published information on this topic has tended to be presented at the state level, rather than the area health service level.
The regular reviewing and reporting of drug and alcohol data is useful in a variety of ways, to a range of key stakeholders interested in the prevention of drug-related harm and the provision of drug and alcohol services in NSW. This information can be used for: informing strategic
DROPS: AN AUTOMATED WEB-BASED SYSTEM FOR THE REPORTING OF DRUG RELATED HEALTH STATISTICS IN NSW
management and policy development; monitoring trends and assisting with response planning; and providing feedback for improved service delivery.
The Centre for Drug and Alcohol and the Centre for Epidemiology and Research perceived a need for an automated system to report on routinely collected data in the drug and alcohol field, which would assist with the preparation of responses to requests for data and also provide regular reports for use in surveillance and planning. Consequently, the Centres collaborated in the development of a web-based interface that contains automaticallyupdated reports on drug related morbidity and mortality in NSW. The system is called Drug Related Outcomes: Population Surveillance (DROPS). A pilot version was tested within the Centre for Drug and Alcohol in mid-2003. After feedback and revision, DROPS was released in early 2004 to a restricted audience of nominated staff in the area health services working in the drug and alcohol field, and staff within the Centre for Drug and Alcohol.
DATA USED IN DROPS
Deaths from opiate overdose is perhaps the most widely used indicator of harm caused by illicit drugs. However, not all injected drugs are illicit and not all illicit drugs are injected. Consequently, DROPS includes data on other drugs and on certain communicable diseases that also indicate levels of harm in the community related to injected and illicit drug use.
Statistics related to psychostimulants (cocaine and amphetamines) and benzodiazepines have been included because these drugs have a high potential for harm in the injecting population. [1] [2] [3] Data on notifications of hepatitis
